- A committee of Japan's Ministry of Health, Labour and Welfare approved AstraZeneca's COVID therapy ( NASDAQ: AZN ) Evusheld.
- The panel also approved the expanded use of Pfizer ( NYSE: PFE ) and BioNTech's ( NASDAQ: BNTX ) COVID-19 vaccine Comirnaty for use in children aged five years to 11 years.
- Earlier in August, U.K. halted procurement of Evusheld (tixagevimab/cilgavimab) citing "insufficient data" on the duration of protection the drug provides against Omicron and subvariants.
For further details see:
Japan approves AstraZeneca COVID drug Evusheld, Pfizer/BioNTech vaccine for kids 5-11